Whole Tumor Antigen Vaccines: Where Are We?

Vaccines

Cheryl Lai-Lai Chiang¹  George Coukos¹  Lana E. Kandalaft¹ 

[1] Ovarian Cancer Research Center, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA; E-Mail:

关键词: vaccines;    dendritic cells;    whole tumor;    personalized vaccines;   

DOI  :  10.3390/vaccines3020344

来源: mdpi

【 摘 要 】

With its vast amount of uncharacterized and characterized T cell epitopes available for activating CD4⁺ T helper and CD8⁺ cytotoxic lymphocytes simultaneously, whole tumor antigen represents an attractive alternative source of antigens as compared to tumor-derived peptides and full-length recombinant tumor proteins for dendritic cell (DC)-based immunotherapy. Unlike defined tumor-derived peptides and proteins, whole tumor lysate therapy is applicable to all patients regardless of their HLA type. DCs are essentially the master regulators of immune response, and are the most potent antigen-presenting cell population for priming and activating naïve T cells to target tumors. Because of these unique properties, numerous DC-based immunotherapies have been initiated in the clinics. In this review, we describe the different types of whole tumor antigens that we could use to pulse DCs ex vivo and in vivo. We also discuss the different routes of delivering whole tumor antigens to DCs in vivo and activating them with toll-like receptor agonists.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.